Guobang Pharmaceutical announced on September 15 that the company recently learned from an inquiry on the “Raw and Auxiliary Package Registration Information” platform of the Drug Evaluation Center of the State Drug Administration that the joint review and approval result of the “cultured dimyristate glyceride” pharmaceutical excipient CDE and formulation submitted by Zhejiang Guobang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, was A. The registration status of excipients changed to A status, which met the supply conditions for commercial production of downstream customer formulations.
Zhitongcaijing · 1d ago
Share
Listen to the news
Guobang Pharmaceutical announced on September 15 that the company recently learned from an inquiry on the “Raw and Auxiliary Package Registration Information” platform of the Drug Evaluation Center of the State Drug Administration that the joint review and approval result of the “cultured dimyristate glyceride” pharmaceutical excipient CDE and formulation submitted by Zhejiang Guobang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, was A. The registration status of excipients changed to A status, which met the supply conditions for commercial production of downstream customer formulations.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending